Highly Purified Eicosapentaenoic Acid Alleviates the Inflammatory Response and Oxidative Stress in Macrophages during Atherosclerosis via the miR‐1a‐3p/sFRP1/Wnt/PCP‐JNK Pathway

Highly purified eicosapentaenoic acid (EPA) has shown great effects in the prevention of atherosclerosis. In a murine model, it significantly reduced plaque accumulation, lowered plasma lipid levels, and decreased inflammation levels, which was also observed in vitro. Using microRNA sequencing, we identified differentially expressed microRNAs, among which miR‐1a‐3p was selected for further validation. Overexpression of miR‐1a‐3p in RAW264.7 cells worsened lipid accumulation, increased oxidative stress, and exacerbated inflammatory responses whereas its downregulation produced the opposite results. Potential targets of miR‐1a‐3p were analyzed by prediction tools. Then, secreted frizzled‐related protein 1 (sFRP1), an antagonist of the Wnt pathway, was confirmed as the target gene of miR‐1a‐3p by a dual‐luciferase reporter assay. Further research showed that in macrophages, EPA influenced the activation of the Wnt/planar cell polarity‐c‐Jun N‐terminal kinase (Wnt/PCP‐JNK) axis, which is consistent with the phenomenon that miR‐1a‐3p has an impact on this same axis. Collectively, our findings suggest that EPA mitigates inflammatory responses and oxidative responses both in vivo and in vitro by targeting the miR‐1a‐3p/sFRP1/Wnt/PCP‐JNK axis in macrophages, which may explain the cardioprotective role of EPA and promote the application of EPA in clinical practice.